Health & Fitness
Health and Fitness
Health and Fitness
Thu, February 12, 2009 BioDelivery Sciences to Present at the ROTH Capital Partners 21st Annual OC Growth Stock Conference
RALEIGH, N.C.--([ BUSINESS WIRE ])--BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a specialty pharmaceutical company focused on developing innovative products to address growing market opportunities using its proprietary drug delivery technologies, today announced that Mark A. Sirgo, Pharm.D., President and Chief Executive Officer will present at the upcoming ROTH Capital Partners 21st Annual Orange County Growth Stock Conference.
Dr. Sirgo's presentation will take place at 12:40 p.m. PST (3:40 p.m. EST) on Monday, February 16, at the Ritz Carlton Laguna Niguel in Dana Point, California. A live webcast and archived presentation can be accessed at [ www.biodeliverysciences.com ].
Dr. Sirgo will be discussing BDSI's lead product, ONSOLIS™, formerly known as BEMA™ Fentanyl. BDSI announced on December 15, 2008, that it had resubmitted its New Drug Application (NDA) for ONSOLIS to the Food and Drug Administration (FDA). The resubmission included the requested Risk Evaluation and Mitigation Strategy (REMS) as requested by FDA. The company anticipates an FDA approval for ONSOLIS during the first half of 2009. Dr. Sirgo will also review the status of the company's pipeline including Bioral™ Amphotericin B and BEMA™ Buprenorphine and expectations for 2009.
The global commercial rights to ONSOLIS, with the exception of Taiwan and South Korea, are licensed to Meda AB.
About BioDelivery Sciences International
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a specialty pharmaceutical company that is focused on developing innovative products to address growing market opportunities, including conditions such as pain. The company utilizes its owned and licensed patented drug delivery technologies to develop, partner, and commercialize new products using proven therapeutics. BDSI's pain franchise currently consists of two products in development utilizing the Company's patented BEMA™ buccal soluble film technology: ONSOLIS (fentanyl buccal soluble film) a potential treatment for "breakthrough" pain in opioid tolerant patients with cancer, and BEMA Buprenorphine, a second analgesic with at least one potential target indication for the treatment of moderate to severe pain. The company is working with its BEMA technology and its patented Bioral cochleate technology on products targeted at conditions common to oncology and surgical patients such as pain and infections. The company headquarters is located in Raleigh, North Carolina, and its principal laboratory is located in Newark, New Jersey. For more information please visit [ www.biodeliverysciences.com ].
Cautionary Note on Forward-Looking Statements
Except for the historical information contained herein, this press release and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects", "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, the results of the Company's clinical trials relating to, and the viability generally of, Bioral™ Amphotericin B generally, may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).
